These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 3116031)

  • 1. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.
    Steingold K; De Ziegler D; Cedars M; Meldrum DR; Lu JK; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1987 Oct; 65(4):773-8. PubMed ID: 3116031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist.
    Chang RJ; Laufer LR; Meldrum DR; DeFazio J; Lu JK; Vale WW; Rivier JE; Judd HL
    J Clin Endocrinol Metab; 1983 May; 56(5):897-903. PubMed ID: 6403570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Gonzalez F; Hatala DA; Speroff L
    Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
    Rittmaster RS; Thompson DL
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
    Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
    Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
    Cheung AP; Lu JK; Chang RJ
    Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome.
    Judd HL; Rigg LA; Anderson DC; Yen SS
    J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH analog administration in patients with polycystic ovarian disease.
    Meden-Vrtovec H
    Int J Gynaecol Obstet; 1995 Aug; 50(2):179-83. PubMed ID: 7589755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
    J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
    Christman GM; Randolph JF; Kelch RP; Marshall JC
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease.
    Steingold KA; Lobo RA; Judd HL; Lu JK; Chang RJ
    J Clin Endocrinol Metab; 1986 May; 62(5):1048-51. PubMed ID: 2937800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary-ovarian relationships in polycystic ovary syndrome.
    Baird DT; Corker CS; Davidson DW; Hunter WM; Michie EA; Van Look PF
    J Clin Endocrinol Metab; 1977 Oct; 45(4):798-801. PubMed ID: 334789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome.
    Apter D; Bützow T; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1994 Jul; 79(1):119-25. PubMed ID: 8027216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.